Prognostic Relevance of Recurrent Sites of Gastric Cancer Treated With Curative Resection: A Single Center Retrospective Study
- Author:
Masato HAYASHI
1
;
Takeshi FUJITA
;
Hisayuki MATSUSHITA
Author Information
- Publication Type:Original Article
- From:Journal of Gastric Cancer 2024;24(3):291-299
- CountryRepublic of Korea
- Language:English
-
Abstract:
Purpose:Gastric cancer treated with curative resection exhibits several recurrence patterns.The peritoneum is the most common site of recurrence. Some reports have indicated different prognostic influences according to the recurrence sites in other cancers, such as esophageal and colorectal cancers. This study investigated whether the recurrence sites influenced the prognosis of patients with recurrent gastric cancer.
Materials and Methods:The data of 115 patients who experienced tumor recurrence after curative gastrectomy were retrospectively reviewed. The sites of recurrence were divided into 4 groups: lymph node (LN), peritoneum, other single organs, and multiple lesions.Clinicopathological features were compared between the sites of recurrence. Prognosis after resection and recurrence were also compared.
Results:The peritoneum was the primary site of recurrence in 38 patients (33%). The tumor differentiation and pathological stages were significantly different. Survival after surgery did not show a statistically significant difference (hazard ratio [HR] of LN: 1, peritoneum: 1.083, other single organs: 1.025, and multiple lesions: 1.058; P=1.00). Survival after recurrence was significantly different (HR of LN, 1; peritoneum, 2.164; other single organs, 1.092; multiple lesions, 1.554; P=0.01), and patients with peritoneal and multiple lesion recurrences had worse prognosis. Furthermore, peritoneal recurrence seemed to occur later than that at other sites; the median times to recurrence in LN, peritoneal, other single-organ, and multiple lesions were 265, 722, 372, and 325 days, respectively.
Conclusions:The sites of gastric cancer recurrence may have different prognostic effects.Peritoneal recurrence may be less sensitive to chemotherapy and occur during the late phase of recurrence.
